BRCA Testing Recommendation
You should undergo BRCA1/BRCA2 genetic testing if you meet specific personal or family history criteria, as genetic testing can directly impact your cancer prevention strategies, treatment decisions, and survival outcomes.
Who Should Be Tested
Based on the most recent ASCO and NCCN guidelines 1, 2, 3, you should pursue BRCA testing if you have:
Personal History Criteria
Breast Cancer:
- Diagnosed at age ≤45 years
- Diagnosed at age ≤50 years AND have a close blood relative with breast cancer ≤50 years
- Triple-negative breast cancer diagnosed at age ≤60 years
- Two primary breast cancers (bilateral or two separate tumors), especially if first diagnosis before age 50
- Male breast cancer at any age
- Ashkenazi Jewish ancestry with breast cancer at any age
Ovarian Cancer:
- Any epithelial ovarian, fallopian tube, or primary peritoneal cancer (excluding mucinous types) at any age 1
Family History Criteria
You should be tested if you have:
- A first-degree relative (parent, sibling, child) with a known BRCA1/2 mutation
- One or more close blood relatives with ovarian cancer at any age
- Two or more close blood relatives with breast and/or ovarian cancer at any age
- A close male blood relative with breast cancer
- Ashkenazi Jewish ancestry with pancreatic cancer at any age 1, 4
Important caveat: The 2024 ASCO-SSO guideline 2 now recommends considering testing for all women with breast cancer up to age 65, as traditional family history-based criteria miss 13-30% of BRCA mutation carriers. This reflects recognition that limited family structure (small families, few female relatives) can mask hereditary risk.
Why Testing Matters for Your Outcomes
Mortality Benefits
For newly diagnosed breast cancer patients: Knowing your BRCA status before surgery allows you to make informed decisions about bilateral mastectomy versus lumpectomy, which directly impacts your risk of second primary cancers 2. The OlympiA trial demonstrated that BRCA-positive patients with high-risk breast cancer who receive adjuvant olaparib (a PARP inhibitor) have improved overall survival 2.
For ovarian cancer patients: BRCA testing should ideally occur at diagnosis 1 because it determines eligibility for PARP inhibitor maintenance therapy, which significantly extends progression-free survival.
Prevention Benefits
If you test positive but haven't had cancer:
- Risk-reducing salpingo-oophorectomy (removing ovaries and fallopian tubes) between ages 35-40 reduces ovarian cancer risk by approximately 80-90% and also decreases breast cancer risk 4, 3
- Risk-reducing mastectomy reduces breast cancer risk by approximately 90% 4, 3
- Enhanced surveillance with annual mammography plus breast MRI starting at age 25-30 enables earlier cancer detection 4, 3
Family Implications
A positive result has critical implications for your blood relatives, who have a 50% chance of carrying the same mutation. This allows them to pursue preventive measures before cancer develops 1.
The Testing Process
Genetic counseling is mandatory before and after testing 1. This discussion must cover:
- Probability of finding a mutation based on your history
- Implications for you and your family members
- Meaning of possible results (positive, negative, variant of uncertain significance)
- Psychological and insurance implications
Testing should not delay cancer treatment if you're newly diagnosed 1.
Testing must occur in a CLIA-approved laboratory 1.
Beyond BRCA1/2
If you're undergoing BRCA testing, you should also be offered testing for other cancer predisposition genes based on your history 2. Among BRCA-negative patients with early-onset breast cancer, 11% carry pathogenic variants in other high-risk genes like PALB2, TP53, PTEN, or CDH1 2. These findings also impact management.
Common Pitfalls to Avoid
Don't assume you're not at risk because you have limited family history. Small families, few female relatives, or relatives who died young from other causes can mask hereditary risk 4, 2. The USPSTF 5 recommends using validated risk assessment tools rather than informal family history review.
Don't wait. If you have ovarian cancer, testing at diagnosis rather than after treatment completion allows you to access targeted therapies immediately 1, 6.
Don't test only tumor tissue. If you have cancer, germline (blood) testing should be done first. If negative, then consider tumor testing for somatic mutations 1. This distinction matters because germline mutations affect your family members while somatic mutations do not.
Special Populations
Ashkenazi Jewish ancestry: Initial testing for the three founder mutations (185delAG and 5382insC in BRCA1; 6174delT in BRCA2) is appropriate, with full sequencing if negative and other criteria are met 4.
Men with prostate cancer: Consider BRCA testing if you have metastatic castration-resistant prostate cancer, as BRCA2 mutations occur in approximately 11% of male breast cancer patients and affect treatment options 7.